AbCellera Biologics Inc. Files 8-K on Shareholder Matters
Ticker: ABCL · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1703057
| Field | Detail |
|---|---|
| Company | Abcellera Biologics INC. (ABCL) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ABCL
TL;DR
AbCellera held a shareholder vote on June 12th, details filed today.
AI Summary
AbCellera Biologics Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details the company's corporate information, including its principal executive office in Vancouver, BC.
Why It Matters
This filing indicates that AbCellera Biologics Inc. has held or is holding a vote of its security holders, which could pertain to significant corporate decisions or governance changes.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- AbCellera Biologics Inc. (company) — Registrant
- June 12, 2025 (date) — Date of earliest event reported
- June 13, 2025 (date) — Filing Date
- Vancouver, BC (location) — Principal executive office location
FAQ
What specific matters were submitted to a vote of AbCellera Biologics Inc.'s security holders?
The filing does not specify the exact matters submitted to a vote, only that such matters were reported on as of June 12, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 12, 2025.
What is AbCellera Biologics Inc.'s principal executive office address?
The principal executive office is located at 150 W 4th Avenue, Vancouver, BC V5Y 1G6.
What is the Commission File Number for AbCellera Biologics Inc.?
The Commission File Number is 001-39781.
Under which section of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding AbCellera Biologics Inc. (ABCL).